FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study.
Cyril Roussel-SimoninPaul GougisDonia LassouedAurore VozyMarianne VeyriLaetitia MorardetJohanna WassermannHervé Foka TichoueLoïc JaffrelotLamia HassaniAlexandre PerrierSebastien BergeretLaurent TailladeJean-Philippe SpanoLuca CampedelBaptiste AbbarPublished in: Acta oncologica (Stockholm, Sweden) (2023)
FOLFIRI showed some activity for platinum-resistant/refractory SCLC in terms of overall response and had an acceptable safety profile. However, caution is needed in interpreting this result. FOLFIRI could represent a potential new treatment for platinum-resistant/refractory SCLC patients. Further prospective studies are needed to assess the benefits of this chemotherapy regimen.HIGHLIGHTSFOLFIRI showed some activity for platinum-resistant/refractory SCLC in terms of overall response.FOLFIRI was well-tolerated in platinum resistant/refractory SLCL patients.FOLFIRI could represent a potential new treatment for SCLC, prospective studies are needed.